BPC-157 and GHK-Cu turn up on the same vendor pages, in the same “healing stack” blends, and under the same shelf label: recovery peptides. That grouping is a marketing artifact. The two compounds share almost nothing — not their origin, not the route they have actually been studied by, not the species their evidence comes from, and not their regulatory footprint. This page compares them on those axes rather than asking which one heals better — no study has ever put them side by side in a human.
The short version: GHK-Cu is a molecule your own body makes, with a small, commercially entangled human literature for what you rub on your skin, and no human data at all for what people inject. BPC-157 is a synthetic sequence with a genuinely large rodent literature for tendon, ligament, and gut injury, no published human efficacy results, and the explicit attention of both the FDA and WADA.
Head-to-head
| Dimension | BPC-157 | GHK-Cu |
|---|---|---|
| Origin & molecule | Synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) based on a fragment of a human gastric juice protein. Not found as such in the body. | Endogenous human tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II), ~403 Da. Present in plasma, saliva, and urine. |
| Primary route studied | Intraperitoneal or intragastric dosing in rats; oral drinking-water dosing in some models. No published human route data. | Topical application to skin (creams, serums, wound gels). No published human injectable data. |
| Evidence tier & species | Preclinical. Hundreds of rodent studies; zero published human efficacy RCT results. | Small controlled human studies for topical cosmetic endpoints; preclinical (rat, cell culture) for everything else. |
| Cosmetic vs systemic framing | Systemic/structural: tendon, ligament, muscle, gut, and nervous-system models. | Cosmetic-first: skin appearance, density, and wound closure. Systemic claims are extrapolated, not tested. |
| Regulatory status | Not approved anywhere. Named on the FDA's bulk-substances list of compounds that may present significant safety risks in compounding. | Not an approved drug for any indication. Legal as a cosmetic ingredient; injectable vials sit outside any regulatory framework. |
| Anti-doping | Named explicitly in WADA category S0 (Non-Approved Substances); prohibited at all times. | Not named on the WADA Prohibited List. S0's catch-all wording is broad, so status of an unapproved injectable form is not something to assume. |
One is native, one is invented
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine carrying a copper ion. It circulates in human plasma at roughly 200 ng/mL around age 20, falling to about 80 ng/mL by age 60, according to a review from the group that has driven most of this field's work (Pickart et al., BioMed Research International 2015). That decline-with-age framing is the entire anti-aging pitch: restore a molecule the body used to have more of.
BPC-157 has no such story. It is a synthetic 15-amino-acid sequence derived from a protective protein in gastric juice, assembled by Predrag Sikirić's group in Zagreb in the early 1990s. The intact pentadecapeptide is not something that has been isolated from human tissue and measured the way GHK has. Its rationale is not replacement — it is that the sequence does interesting things in injured rats.
The evidence bases do not overlap
BPC-157: deep in rodents, empty in humans
The animal work is real and reasonably specific. In transected rat Achilles tendons, intraperitoneal BPC-157 at 10 µg, 10 ng, or 10 pg per kg daily for 14 days improved load capacity, elasticity, functional scores, and collagen organization versus saline (Staresinic et al., J Orthop Res 2003). In rat medial collateral ligament transection followed for 90 days, improvements appeared whether the peptide was injected, applied topically, or given in drinking water (Cerovecki et al., J Orthop Res 2010). At the cell level, BPC-157 increased rat tendon fibroblast outgrowth, survival under oxidative stress, and dose-dependent migration, with phosphorylation of FAK and paxillin rising in step (Chang et al., J Appl Physiol 2011).
The human column is blank. A 2025 literature and patent review concluded that no completed clinical studies describe BPC-157's efficacy in humans, and recorded that a Phase I trial begun in 2015 in 42 healthy volunteers ended with the researchers cancelling submission of the results in 2016 (Józwiak et al., Pharmaceuticals 2025). The most recent controlled comparison is still in rats: 32 male Sprague-Dawley animals given BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both after Achilles transection, where TB-500 reached statistical significance on load-to-failure and Bonar histology scores (p = 0.016) while BPC-157 did not, and the combination added nothing (Biçer et al., Jt Dis Relat Surg 2026). That study is covered in more depth on the BPC-157 vs TB-500 comparison.
GHK-Cu: shallow, but at least some of it is human
GHK-Cu's human evidence exists, is topical, and comes with an asterisk. The most-quoted results — a 12-week facial cream study in 71 women reporting improved skin density and reduced wrinkle depth, an eye-cream study in 41 women, and thigh-skin collagen comparisons against vitamin C and retinoic acid — reach readers mainly through reviews written by Loren Pickart and Anna Margolina of Skin Biology, a company that sells copper-peptide products (Pickart & Margolina, Int J Mol Sci 2018). The same review is the source of the widely repeated claim that GHK shifts expression of 31.2% of human genes by 50% or more. That affiliation does not make the findings false; it means the synthesis is an interested party's, not an independent audit's.
The one clearly independent randomized trial points the other way. Thirteen patients who completed a study of GHK-Cu products after CO2 laser resurfacing showed no statistically significant advantage on objective measures — blinded evaluation and computer analysis found no difference in erythema resolution, wrinkles, or overall skin quality. What did differ was self-report: patients using GHK-Cu rated their post-treatment skin quality better (P = .04) (Miller et al., Arch Facial Plast Surg 2006). A null objective result in 13 people is not proof of nothing, but it is the closest thing to an unconflicted human test this compound has, and it did not reproduce the industry findings.
Below the human tier, GHK-Cu's animal data are also topical. In 24 rats with ischemic full-thickness wounds, topical tripeptide-copper complex produced 64.5% wound-area reduction by day 13 versus 45.6% for vehicle and 28.2% for untreated controls, with lower TNF-alpha, MMP-2, and MMP-9 (Canapp et al., Vet Surg 2003). The most-cited systemic finding is not a treatment study at all: a genomics analysis of emphysema-damaged lung identified 127 severity-associated genes and flagged GHK computationally as a compound whose signature reversed theirs, then showed it restored collagen remodeling in fibroblasts from COPD lungs (Campbell et al., Genome Medicine 2012). Interesting; not evidence that injecting GHK-Cu does anything in a person.
Route is the real fork in the road
Comparing these two on efficacy quietly assumes they are used the same way. They are not. Essentially all of GHK-Cu's human evidence involves putting it on skin, where the copper load is small and absorption through an intact barrier is limited. Essentially all of BPC-157's evidence involves getting it inside an animal. When someone injects GHK-Cu — the form sold as lyophilized vials for “research use” — they have left the literature entirely, not moved to a stronger dose of it.
So the honest framing of the two is: BPC-157 is a systemic experimental compound with no human data, and GHK-Cu is a topical cosmetic ingredient with modest human data that is frequently sold in a systemic form with no human data. Both end in the same place for anyone considering an injection, but they arrive there from opposite directions.
Only one of them delivers a metal
GHK-Cu is a copper carrier, and that is a category of question BPC-157 simply does not raise. Copper is about 16% of GHK-Cu by weight, so a 2 mg dose carries roughly 0.3 mg of elemental copper. For adults the RDA is 900 mcg/day and the tolerable upper intake level is 10,000 mcg (10 mg)/day, a ceiling the Food and Nutrition Board set on the basis of liver damage (NIH Office of Dietary Supplements). Those figures describe oral intake, where the gut regulates how much copper is absorbed. Injection bypasses that gatekeeper, and no published study has measured what repeated parenteral GHK-Cu does to copper balance in humans. People with copper-handling disorders such as Wilson disease have an obvious reason to treat any copper-delivering product differently.
Regulators treat them very differently
BPC-157 is named on the FDA's list of bulk drug substances that may present significant safety risks in compounding. The entry states that compounded BPC-157 “may pose risk for immunogenicity for certain routes of administration,” has complexities with peptide-related impurities and API characterization, and that FDA “has identified no, or only limited, safety-related information for the proposed routes of administration” — leaving the agency without enough information to know whether it would cause harm (FDA bulk drug substances list). GHK-Cu is not on that list. Its regulatory identity is as a cosmetic ingredient, which is legal — and which says nothing about injectable vials, because cosmetic status does not travel with a molecule into a syringe.
In sport the asymmetry is sharper. WADA's S0 category covers pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use, prohibits them at all times, and names BPC-157 explicitly among its examples (WADA Prohibited List). GHK-Cu is not named anywhere on the List. That absence is not the same as clearance: S0 is a catch-all defined by approval status rather than by a roster of names, and WADA's own guidance is that a substance not found on the List should be checked with an athlete's Anti-Doping Organization rather than assumed permitted.
How to read a stack that contains both
Blends pairing BPC-157 with GHK-Cu (often alongside TB-500) are common, and the rationale offered is usually that they cover different parts of healing. The mechanistic story is coherent enough — angiogenesis and fibroblast behavior for one, copper-dependent collagen enzymes for the other. What the story omits is that a combination inherits every unknown of both components and adds interaction questions nobody has studied. The single existing head-to-head test of a healing-peptide combination, in rats, found no synergy over either agent alone (Biçer et al. 2026).
If you are evaluating claims about either compound, the useful questions are the ones this page is organized around: which species produced the result, which route was used, who funded or authored the synthesis you are reading, and whether the endpoint was measured or self-reported. Those four filters separate almost everything real in this literature from almost everything oversold in it.
Dive deeper
- BPC-157 overview · benefits · side effects · dosing concepts · research
- GHK-Cu overview · benefits · side effects · dosing concepts · research
- Related molecules: TB-500 · AHK-Cu (the hair-focused copper peptide)
- Related comparison: BPC-157 vs TB-500 · all comparisons
- General context: what are the risks of peptides · who should avoid using peptides · what are the downsides to peptides · why some doctors do not prescribe peptides
This page is educational and non-prescriptive. It describes what has been published about these two compounds and does not recommend, or advise against, using either.